<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font9" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font11" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font12" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="306" width="62" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text"><b>Available online</b></text>
<text top="42" left="370" width="186" height="7" font="font3" id="p1_t3" reading_order_no="1" segment_no="0" tag_type="text">http://breast-cancer-research.com/content/7/6/R1159</text>
<text top="735" left="569" width="23" height="8" font="font4" id="p1_t4" reading_order_no="104" segment_no="23" tag_type="text">R1159</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t5" reading_order_no="4" segment_no="2" tag_type="title">Vol 7 No 6</text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="464" height="14" font="font7" id="p1_t7" reading_order_no="5" segment_no="3" tag_type="title"><b>Farnesyl-transferase inhibitor R115,777 enhances tamoxifen </b></text>
<text top="120" left="57" width="446" height="14" font="font7" id="p1_t8" reading_order_no="6" segment_no="3" tag_type="title"><b>inhibition of MCF-7 cell growth through estrogen receptor </b></text>
<text top="138" left="57" width="292" height="14" font="font7" id="p1_t9" reading_order_no="7" segment_no="3" tag_type="title"><b>dependent and independent pathways</b></text>
<text top="156" left="57" width="83" height="11" font="font8" id="p1_t10" reading_order_no="8" segment_no="4" tag_type="text">Florence Dalenc</text>
<text top="155" left="140" width="19" height="8" font="font3" id="p1_t11" reading_order_no="9" segment_no="4" tag_type="text">1,2,3</text>
<text top="156" left="159" width="91" height="11" font="font8" id="p1_t12" reading_order_no="10" segment_no="4" tag_type="text">, Claire Giamarchi</text>
<text top="155" left="250" width="19" height="8" font="font3" id="p1_t13" reading_order_no="11" segment_no="4" tag_type="text">1,2,3</text>
<text top="156" left="269" width="71" height="11" font="font8" id="p1_t14" reading_order_no="12" segment_no="4" tag_type="text">, Mélissa Petit</text>
<text top="155" left="339" width="19" height="8" font="font3" id="p1_t15" reading_order_no="13" segment_no="4" tag_type="text">1,2,3</text>
<text top="156" left="358" width="65" height="11" font="font8" id="p1_t16" reading_order_no="14" segment_no="4" tag_type="text">, Marc Poirot</text>
<text top="155" left="423" width="19" height="8" font="font3" id="p1_t17" reading_order_no="15" segment_no="4" tag_type="text">1,2,3</text>
<text top="156" left="442" width="66" height="11" font="font8" id="p1_t18" reading_order_no="16" segment_no="4" tag_type="text">, Gilles Favre</text>
<text top="155" left="508" width="19" height="8" font="font3" id="p1_t19" reading_order_no="17" segment_no="4" tag_type="text">1,2,3</text>
<text top="156" left="526" width="25" height="11" font="font8" id="p1_t20" reading_order_no="18" segment_no="4" tag_type="text"> and </text>
<text top="172" left="57" width="93" height="11" font="font8" id="p1_t21" reading_order_no="19" segment_no="4" tag_type="text">Jean-Charles Faye</text>
<text top="171" left="150" width="19" height="8" font="font3" id="p1_t22" reading_order_no="20" segment_no="4" tag_type="text">1,2,3</text>
<text top="205" left="57" width="3" height="5" font="font9" id="p1_t23" reading_order_no="21" segment_no="5" tag_type="text">1</text>
<text top="205" left="60" width="393" height="7" font="font3" id="p1_t24" reading_order_no="22" segment_no="5" tag_type="text">INSERM U563, CPTP, Département Innovation Thérapeutique et Oncologie Moléculaire, Toulouse F-31052, France</text>
<text top="214" left="57" width="3" height="5" font="font9" id="p1_t25" reading_order_no="23" segment_no="6" tag_type="text">2</text>
<text top="215" left="60" width="292" height="7" font="font3" id="p1_t26" reading_order_no="24" segment_no="6" tag_type="text">Institut Claudius Regaud, 42 rue du pont Saint Pierre, 31052 Toulouse Cédex, France</text>
<text top="224" left="57" width="3" height="5" font="font9" id="p1_t27" reading_order_no="25" segment_no="7" tag_type="text">3</text>
<text top="224" left="60" width="176" height="7" font="font3" id="p1_t28" reading_order_no="26" segment_no="7" tag_type="text">Université Paul Sabatier, Toulouse F-31062, France</text>
<text top="242" left="57" width="203" height="7" font="font3" id="p1_t29" reading_order_no="27" segment_no="8" tag_type="text">Corresponding author: Jean-Charles Faye, faye@icr.fnclcc.fr</text>
<text top="260" left="57" width="253" height="7" font="font3" id="p1_t30" reading_order_no="28" segment_no="9" tag_type="text">Received: 9 Sep 2005 Accepted: 26 Oct 2005 Published: 21 Nov 2005</text>
<text top="279" left="57" width="85" height="7" font="font10" id="p1_t31" reading_order_no="29" segment_no="10" tag_type="text"><i>Breast Cancer Research</i></text>
<text top="279" left="141" width="25" height="7" font="font3" id="p1_t32" reading_order_no="30" segment_no="10" tag_type="text"> 2005, </text>
<text top="279" left="166" width="4" height="7" font="font2" id="p1_t33" reading_order_no="31" segment_no="10" tag_type="text"><b>7</b></text>
<text top="279" left="171" width="138" height="7" font="font3" id="p1_t34" reading_order_no="32" segment_no="10" tag_type="text">:R1159-R1167 (DOI 10.1186/bcr1357)</text>
<text top="289" left="57" width="265" height="7" font="font3" id="p1_t35" reading_order_no="33" segment_no="11" tag_type="text"><a href="http://breast-cancer-research.com/content/7/6/R1159">This article is online at: http://breast-cancer-research.com/content/7/6/R1159</a></text>
<text top="299" left="57" width="53" height="7" font="font3" id="p1_t36" reading_order_no="34" segment_no="12" tag_type="text">© 2005 Dalenc</text>
<text top="299" left="110" width="17" height="7" font="font10" id="p1_t37" reading_order_no="35" segment_no="12" tag_type="text"><i> et al</i></text>
<text top="299" left="127" width="107" height="7" font="font3" id="p1_t38" reading_order_no="36" segment_no="12" tag_type="text">.; licensee BioMed Central Ltd. </text>
<text top="309" left="57" width="491" height="7" font="font3" id="p1_t39" reading_order_no="37" segment_no="13" tag_type="text">This is an open occess article distributed under the terms of the Creative Commons Attribution Licens<a href="http://creativecommons.org/licenses/by/2.0">e (http://creativecommons.org/licenses/by/</a></text>
<text top="319" left="57" width="426" height="7" font="font3" id="p1_t40" reading_order_no="38" segment_no="13" tag_type="text"><a href="http://creativecommons.org/licenses/by/2.0">2.0),</a> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="349" left="57" width="43" height="10" font="font11" id="p1_t41" reading_order_no="39" segment_no="14" tag_type="title"><b>Abstract</b></text>
<text top="369" left="57" width="49" height="8" font="font12" id="p1_t42" reading_order_no="40" segment_no="15" tag_type="text"><b>Introduction</b></text>
<text top="369" left="106" width="191" height="8" font="font13" id="p1_t43" reading_order_no="41" segment_no="15" tag_type="text"> We have previously shown that FTI-277, a farnesyl</text>
<text top="379" left="57" width="240" height="8" font="font13" id="p1_t44" reading_order_no="42" segment_no="15" tag_type="text">transferase inhibitor (FTI), enhances the efficacy of tamoxifen</text>
<text top="390" left="57" width="240" height="8" font="font13" id="p1_t45" reading_order_no="43" segment_no="15" tag_type="text">(Tam) in inhibiting the proliferation of the estrogen dependent</text>
<text top="400" left="57" width="240" height="8" font="font13" id="p1_t46" reading_order_no="44" segment_no="15" tag_type="text">MCF-7 cell line. As the cellular response to Tam is the result of</text>
<text top="411" left="57" width="241" height="8" font="font13" id="p1_t47" reading_order_no="45" segment_no="15" tag_type="text">an inhibition of both estrogen receptor-dependent and -</text>
<text top="421" left="57" width="240" height="8" font="font13" id="p1_t48" reading_order_no="46" segment_no="15" tag_type="text">independent pathways, we have used the estrogen receptor</text>
<text top="432" left="57" width="240" height="8" font="font13" id="p1_t49" reading_order_no="47" segment_no="15" tag_type="text">selective anti-estrogen ICI182,780 and N-pyrrolidine(-</text>
<text top="442" left="57" width="240" height="8" font="font13" id="p1_t50" reading_order_no="48" segment_no="15" tag_type="text">phenylmethyl-phenoxy)-ethanamine-HCl (PBPE), a selective</text>
<text top="453" left="57" width="240" height="8" font="font13" id="p1_t51" reading_order_no="49" segment_no="15" tag_type="text">ligand of anti-estrogen binding site (AEBS), to dissect out the</text>
<text top="463" left="57" width="240" height="8" font="font13" id="p1_t52" reading_order_no="50" segment_no="15" tag_type="text">mechanism(s) associated with the observed additivity resulting</text>
<text top="474" left="57" width="240" height="8" font="font13" id="p1_t53" reading_order_no="51" segment_no="15" tag_type="text">from combination treatment with FTI-277 and Tam. Moreover,</text>
<text top="484" left="57" width="240" height="8" font="font13" id="p1_t54" reading_order_no="52" segment_no="15" tag_type="text">for these studies, FTI-277 has been replaced by R115,777, a</text>
<text top="495" left="57" width="141" height="8" font="font13" id="p1_t55" reading_order_no="53" segment_no="15" tag_type="text">FTI currently in phase III clinical trials.</text>
<text top="516" left="57" width="36" height="8" font="font12" id="p1_t56" reading_order_no="54" segment_no="18" tag_type="text"><b>Methods</b></text>
<text top="516" left="92" width="205" height="8" font="font13" id="p1_t57" reading_order_no="55" segment_no="18" tag_type="text"> The quantitative sulphorhodamine B (SRB)</text>
<text top="526" left="57" width="240" height="8" font="font13" id="p1_t58" reading_order_no="56" segment_no="18" tag_type="text">colorimetric assay was used to determine the growth inhibitory</text>
<text top="537" left="57" width="240" height="8" font="font13" id="p1_t59" reading_order_no="57" segment_no="18" tag_type="text">effect of agents on MCF-7 cells. Dose response interactions</text>
<text top="547" left="57" width="240" height="8" font="font13" id="p1_t60" reading_order_no="58" segment_no="18" tag_type="text">between R115,777-Tam, R115,777-ICI182,780 and</text>
<text top="558" left="57" width="169" height="8" font="font13" id="p1_t61" reading_order_no="59" segment_no="18" tag_type="text">R115,777-PBPE were evaluated, at the IC</text>
<text top="562" left="226" width="9" height="6" font="font9" id="p1_t62" reading_order_no="60" segment_no="18" tag_type="text">50 </text>
<text top="558" left="236" width="61" height="8" font="font13" id="p1_t63" reading_order_no="61" segment_no="18" tag_type="text">point, using the</text>
<text top="568" left="57" width="240" height="8" font="font13" id="p1_t64" reading_order_no="62" segment_no="18" tag_type="text">isobologram method. Apoptotic cell death (DNA fragmentation,</text>
<text top="579" left="57" width="240" height="8" font="font13" id="p1_t65" reading_order_no="63" segment_no="18" tag_type="text">nucleus condensation and cytokeratin 18 cleavage) and</text>
<text top="589" left="57" width="240" height="8" font="font13" id="p1_t66" reading_order_no="64" segment_no="18" tag_type="text">inhibition of the mevalonate pathway (western blot) were also</text>
<text top="600" left="57" width="45" height="8" font="font13" id="p1_t67" reading_order_no="65" segment_no="18" tag_type="text">determined.</text>
<text top="369" left="315" width="31" height="8" font="font12" id="p1_t68" reading_order_no="66" segment_no="16" tag_type="text"><b>Results</b></text>
<text top="369" left="346" width="210" height="8" font="font13" id="p1_t69" reading_order_no="67" segment_no="16" tag_type="text"> Combinations of the specific FTI R115,777 with either</text>
<text top="379" left="315" width="240" height="8" font="font13" id="p1_t70" reading_order_no="68" segment_no="16" tag_type="text">ICI182,780 or PBPE exhibit a synergistic effect on MCF-7 cell</text>
<text top="390" left="315" width="240" height="8" font="font13" id="p1_t71" reading_order_no="69" segment_no="16" tag_type="text">growth inhibition, while its combination with Tam is additive, as</text>
<text top="400" left="315" width="240" height="8" font="font13" id="p1_t72" reading_order_no="70" segment_no="16" tag_type="text">previously reported for FTI-277. Apoptosis is detected after</text>
<text top="411" left="315" width="240" height="8" font="font13" id="p1_t73" reading_order_no="71" segment_no="16" tag_type="text">treatment with combinations of R115,777 with either Tam or</text>
<text top="421" left="315" width="240" height="8" font="font13" id="p1_t74" reading_order_no="72" segment_no="16" tag_type="text">PBPE but not with ICI182,780, suggesting that each</text>
<text top="432" left="315" width="241" height="8" font="font13" id="p1_t75" reading_order_no="73" segment_no="16" tag_type="text">combination inhibits cell proliferation by different mechanisms.</text>
<text top="442" left="315" width="241" height="8" font="font13" id="p1_t76" reading_order_no="74" segment_no="16" tag_type="text">Even though the ER pathway has not yet been deciphered, it is</text>
<text top="453" left="315" width="240" height="8" font="font13" id="p1_t77" reading_order_no="75" segment_no="16" tag_type="text">shown here that the AEBS pathway is able to interfere with the</text>
<text top="463" left="315" width="212" height="8" font="font13" id="p1_t78" reading_order_no="76" segment_no="16" tag_type="text">mevalonate pathway at the level of protein farnesylation.</text>
<text top="484" left="315" width="46" height="8" font="font12" id="p1_t79" reading_order_no="77" segment_no="17" tag_type="text"><b>Conclusion</b></text>
<text top="484" left="361" width="195" height="8" font="font13" id="p1_t80" reading_order_no="78" segment_no="17" tag_type="text"> Overall, this work reveals that combinations of</text>
<text top="495" left="315" width="240" height="8" font="font13" id="p1_t81" reading_order_no="79" segment_no="17" tag_type="text">R115,777 with either selective ER ligands or a selective AEBS</text>
<text top="505" left="315" width="240" height="8" font="font13" id="p1_t82" reading_order_no="80" segment_no="17" tag_type="text">ligand are able to induce large increases in their anti-proliferative</text>
<text top="516" left="315" width="240" height="8" font="font13" id="p1_t83" reading_order_no="81" segment_no="17" tag_type="text">activities on MCF-7 cells. Moreover, these results suggest that</text>
<text top="526" left="315" width="240" height="8" font="font13" id="p1_t84" reading_order_no="82" segment_no="17" tag_type="text">it may be of definite interest to evaluate combinations of</text>
<text top="537" left="315" width="240" height="8" font="font13" id="p1_t85" reading_order_no="83" segment_no="17" tag_type="text">R115,777 with different anti-estrogens in the treatment of ER</text>
<text top="547" left="315" width="240" height="8" font="font13" id="p1_t86" reading_order_no="84" segment_no="17" tag_type="text">positive breast tumours. Based on these experimental data,</text>
<text top="558" left="315" width="240" height="8" font="font13" id="p1_t87" reading_order_no="85" segment_no="17" tag_type="text">such combinations may prove beneficial in different clinical</text>
<text top="568" left="315" width="240" height="8" font="font13" id="p1_t88" reading_order_no="86" segment_no="17" tag_type="text">scenarios or when used in specific sequences; studying the</text>
<text top="579" left="315" width="240" height="8" font="font13" id="p1_t89" reading_order_no="87" segment_no="17" tag_type="text">combination of R115,777 with ICI182,780 for early treatment</text>
<text top="589" left="315" width="240" height="8" font="font13" id="p1_t90" reading_order_no="88" segment_no="17" tag_type="text">and reserving combinations with either Tam or a selective AEBS</text>
<text top="600" left="315" width="231" height="8" font="font13" id="p1_t91" reading_order_no="89" segment_no="17" tag_type="text">ligand, such as BMS-217380-01, for more resistant disease.</text>
<text top="653" left="57" width="64" height="10" font="font11" id="p1_t92" reading_order_no="90" segment_no="20" tag_type="title"><b>Introduction</b></text>
<text top="665" left="57" width="240" height="9" font="font13" id="p1_t93" reading_order_no="91" segment_no="21" tag_type="text">Tamoxifen (Tam) remains the most frequently prescribed agent</text>
<text top="677" left="57" width="240" height="9" font="font13" id="p1_t94" reading_order_no="92" segment_no="21" tag_type="text">for the treatment of hormone responsive breast cancer. Effi-</text>
<text top="688" left="57" width="240" height="9" font="font13" id="p1_t95" reading_order_no="93" segment_no="21" tag_type="text">cacy for Tam has been demonstrated in the treatment of all</text>
<text top="700" left="57" width="240" height="9" font="font13" id="p1_t96" reading_order_no="94" segment_no="21" tag_type="text">stages of breast cancer and it is also used as prevention ther-</text>
<text top="633" left="315" width="240" height="9" font="font13" id="p1_t97" reading_order_no="95" segment_no="19" tag_type="text">apy for women at high risk of developing breast cancer.</text>
<text top="645" left="315" width="240" height="9" font="font13" id="p1_t98" reading_order_no="96" segment_no="19" tag_type="text">Although Tam is effective initially in many patients, a major</text>
<text top="657" left="315" width="240" height="9" font="font13" id="p1_t99" reading_order_no="97" segment_no="19" tag_type="text">obstacle to its long-term use is tumour resistance. To resolve</text>
<text top="669" left="315" width="240" height="9" font="font13" id="p1_t100" reading_order_no="98" segment_no="19" tag_type="text">this problem, we decided to evaluate the effects of combining</text>
<text top="680" left="315" width="240" height="9" font="font13" id="p1_t101" reading_order_no="99" segment_no="19" tag_type="text">Tam with a farnesyl transferase inhibitor (FTI). Although the</text>
<text top="692" left="315" width="240" height="9" font="font13" id="p1_t102" reading_order_no="100" segment_no="19" tag_type="text">role of combination therapy versus sequential therapies with</text>
<text top="704" left="315" width="240" height="9" font="font13" id="p1_t103" reading_order_no="101" segment_no="19" tag_type="text">single agents remains controversial in the treatment of breast</text>
<text top="724" left="57" width="499" height="7" font="font3" id="p1_t104" reading_order_no="102" segment_no="22" tag_type="footnote">AEBS = anti-estrogen binding site; ER = estrogen receptor; FTI = farnesyl transferase inhibitor; PBPE = N-pyrrolidine(-phenylmethyl-phenoxy)-ethan-</text>
<text top="734" left="57" width="313" height="7" font="font3" id="p1_t105" reading_order_no="103" segment_no="22" tag_type="footnote">amine-HCl; PBS = phosphate-buffered saline; SRB = sulphorhodamine B; Tam = tamoxifen.</text>
</page>
</pdf2xml>
